2024
Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders
Paller A, Rangel S, Chamlin S, Hajek A, Phan S, Hogeling M, Castelo-Soccio L, Lara-Corrales I, Arkin L, Lawley L, Funk T, Lopes F, Antaya R, Ramien M, Vivar K, Teng J, Coughlin C, Rehmus W, Gupta D, Bercovitch L, Stein S, Boull C, Tom W, Liang M, Hunt R, Luu M, Holland K, Schoch J, Cella D, Lai J, Griffith J. Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders. JAMA Dermatology 2024, 160: 621-630. PMID: 38656377, PMCID: PMC11044010, DOI: 10.1001/jamadermatol.2024.0594.Peer-Reviewed Original ResearchQuality of lifeAssociated with mental healthReduced quality of lifeStigma scoresDisease visibilityMental healthPhysician assessmentAssociated with stigmaExtent of stigmaPhysician assessment of disease severityMental health impactsPoor peer relationshipsModerate stigmaPatients aged 8Psychosocial interventionsChronic skin diseaseMain OutcomesIdentified stigmatizationSingle-visit studyChronic diseasesPediatric skin disordersStigmaModerate disease severityIncreased depressionSecondary outcomes
2022
Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants
Mosallaei D, Hao M, Antaya RJ, Levian B, Kwong A, Cogan J, Hamilton C, Schwieger-Briel A, Tan C, Tang X, Woodley DT, Chen M. Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants. JAMA Dermatology 2022, 158: 366-374. PMID: 35234826, PMCID: PMC8892363, DOI: 10.1001/jamadermatol.2021.5992.Peer-Reviewed Original ResearchConceptsNonrandomized clinical trialIntravenous gentamicinJunctional epidermolysis bullosaNonsense variantDermal-epidermal junctionGentamicin treatmentClinical trialsEpidermolysis bullosaPopulation of patientsLaminin-332Low-dose gentamicinTotal activity scoreHome infusion servicesLong-term safetyDisease activityGentamicin therapySecondary outcomesLaminin-332 expressionPediatric patientsPrimary outcomeActivity scoreClinical outcomesAvailable therapiesNephrotoxic effectsOtotoxic effects